Atopic dermatis: dual kinase inhibitor performs well in early trial

  • Bissonnette R & al.
  • Br J Dermatol
  • 28 Mar 2019

  • International Clinical Digest
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • ASN002, an investigational dual inhibitor of Janus kinase (JAK) and spleen tyrosine kinase (SYK), showed good efficacy for moderate to severe atopic dermatitis in a phase 1b randomized controlled trial.

Why this matters

  • Few oral treatments are available for treatment of AD.

Key results

  • ASN002 was associated with superior efficacy compared with placebo:
    • EASI-50 at day 29: 22.2% for placebo, 100.0% for 40 mg (P=.003 vs placebo), 83.3% for 80 mg (P=.03 vs placebo).
    • EASI-75 at day 15: 42.9% for 40 mg (P=.04 vs placebo).
    • Change from baseline in body surface affected at day 29: −3.2 for placebo, −21.6 for 40 mg (P=.03)
    • Change from baseline in pruritus at day 29: −1.6 for placebo, −4.7 for 80 mg (P=.01).
  • ASN002 induced significant and progressive reductions in the AD inflammatory serum signature.
  • 2 adverse events that met the stopping rules occurred: 1 case of mild hypertension in a patient receiving ASN002 80 mg and 1 case of low lymphocyte levels in a patient receiving ASN002 40 mg.

Study design

  • 36 patients with moderate to severe atopic dermatitis were randomly assigned 1:1:1:1 to ASN002 20 mg, ASN002 40 mg, ASN002 80 mg, or placebo over a 28-day period.
  • Funding: Asana BioSciences.

Limitations

  • Small patient sample size.
  • Short treatment duration.